熱門資訊> 正文
美国银行以“快速追随者”的方式启动Biohaven
2024-08-27 02:11
- BofA started coverage of Biohaven (NYSE:BHVN) with a buy rating, citing its drug development programs for mood and autoimmune disorders.
- The investment bank said it liked Biohaven’s “’fast-follower’ approach of advancing drugs that rivals have been developing – allowing it to capitalize on an already de-risked clinical path.”
- BofA added that while it saw Biohaven’s (BHVN) efforts as “expansive,” it believed management had a “track record of prudent capital allocation.”
- The bank set its price objective for the stock at $52.
More on Biohaven
- Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
- Morgan Stanley starts Biohaven at overweight, cites broad pipeline
- Biohaven stock falls 30% premarket amid drug updates
- Seeking Alpha’s Quant Rating on Biohaven
- Historical earnings data for Biohaven
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
